Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SL1CC
- Development stage
- Phase 1
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
SL1CC (also known as SL1CC Injection) is an investigational, *in vivo* chimeric antigen receptor (CAR) T-cell therapy targeting C-type lectin-like molecule-1 (CLL-1, also known as CLEC12A). Developed by researchers at the Chinese PLA General Hospital, SL1CC is designed to generate CAR-T cells directly within the patient's body (*in vivo*) following a single intravenous infusion, bypassing the complex and costly *ex vivo* manufacturing process typically required for autologous CAR-T therapies. It is currently being evaluated in a Phase 1 clinical trial for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML), administered without the need for lymphodepleting conditioning chemotherapy.
- Other names
- SL1CC InjectionSL-1CC InjectionSL 1CC Injection
02
Targets
CLEC12A
Beyond the preview
Go deeper on SL1CC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SL1CC.